The ADME assay development pipeline includes in vitro ADME assays that are necessary once a lead candidate has been selected. The safety profile of a drug candidate will depend partly on its interactions with other drugs, especially those that may be administered concomitantly in standard-of-care treatment. Assessing the risks of possible drug-interactions using validated bioanalytical methods is thus an essential early step in the candidate development process. Q2 Solutions offers a suite of in vitro assays to support drug-drug interaction testing, including cytochrome P450 (CYP) enzyme inhibition (IC50), time-dependent CYP inhibition, induction of CYP enzymes, and CYP reaction phenotyping. All in vitro metabolism assay results are presented in fully QC-reviewed, regulatory-style reports to support filing of IND applications.
Interferon gamma (IFN) ELISpot and FluoroSpot are widely used immune monitoring assays to detect functional cell responses in clinical studies. Recognized for their importance in vaccine development...
In this episode, Dr. Monika Lamba, a pathologist from Q2 Solutions, discusses the transformative role of digital pathology in clinical trials. Despite its origins aiming to streamline trials, it's...
Laval is the mothership site of Nexelis, a Q2 Solutions Company, with a history of success in developing vaccine technology for a broad array of infectious diseases. Download our factsheet to learn...